Evotec SE participates in iCARE4CVD, an international public-private research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-icare4cvd-a-consortium-to-personalise-prevention-and-treatment-of-cardiovascular-diseases-6336